Mirna Therapeutics Reports Third Quarter Financial Results and Recent Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Mirna Therapeutics (MIRN) Posts Wider Q3 Loss
November 13, 2015 7:39 AM ESTMirna Therapeutics (NASDAQ: MIRN) reported Q3 EPS of ($82.16), versus ($73.73) reported last year. The results included non-cash, stock-based compensation charges of approximately $210,000 in the three months ended September 30, 2015 and approximately $101,000 in the same period in 2014.
For earnings history and earnings-related data on Mirna Therapeutics (MIRN) click here.
... More